Katharine Orf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katharine Orf has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Siobhan O. Burns
Institute of Immunity and Transplantation, London, United Kingdom
4 shared publications- Emma Catherine Morris
Institute of Immunity and Transplantation, University College London, London, United Kingdom
3 shared publications - Thomas Andrew Fox
Institute of Immunity and Transplantation, University College London, London, United Kingdom
3 shared publications - Adriana S. Albuquerque
Institute of Immunity and Transplantation, University College London, London, United Kingdom
2 shared publications - Christoph Matti
University College London, London, United Kingdom
2 shared publications - Claire Booth
UCL GOSH Institute of Child Health, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 20 November 2026
- Published by American Society of Hematology in Blood Advances
Base Editing of Hematopoietic Stem Cells Corrects Gain-of-Function Mutations in APDS
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS1, APDS2) are rare gain-of-function inborn errors of immunity (IEI) leading to recurrent severe infections, bronchiectasis, lymphoproliferation and lymphoma. APDS1 and APDS2 are caused by mutations in PIK3CD and PIK3R1 respectively, which together encode the subunits of the phosphoinositide 3-kinase enzyme (PI3K). The only curative therapy is allogeneic hematopoietic stem cell transplantation (alloHSCT), which requires a suitable donor and incurs a significant risk of morbidity and mortality. An adenine base editing strategy was developed to target the most frequent point mutations in APDS1 (p.E1021K, c.3061G>A; ~90% of patients) and APDS2 (c.1425+1G > A; ~50% of patients). Highly efficient correction of the pathogenic point mutation was achieved in patient T cells and hematopoietic stem cells (HSCs) and associated with functional restoration of PI3K signaling, rescue of the activation-induced cell death phenotype and, in APDS2, abrogated expression of the pathogenic splice isoform. Edited HSCs maintained pluripotency and achieved long-term engraftment in immunodeficient mice. A healthy control:APDS1 mixed chimera mouse model suggested that 75% wild-type engraftment generated a wild-type phenotype with respect to T and B cell dysfunction and lymphoproliferation, and thus similar editing efficiencies would be predicted to improve patient clinical phenotype. Together, these data demonstrate successful application of base editing to a gain-of-function IEI, with potential for application in other diseases.
- 20 November 2026
- Published by American Society of Hematology in Blood Advances
Open AccessBase Editing of Hematopoietic Stem Cells Corrects Gain-of-Function Mutations in APDS
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS1, APDS2) are rare gain-of-function inborn errors of immunity (IEI) leading to recurrent severe infections, bronchiectasis, lymphoproliferation and lymphoma. APDS1 and APDS2 are caused by mutations in PIK3CD and PIK3R1 respectively, which together encode the subunits of the phosphoinositide 3-kinase enzyme (PI3K). The only curative therapy is allogeneic hematopoietic stem cell transplantation (alloHSCT), which requires a suitable donor and incurs a significant risk of morbidity and mortality. An adenine base editing strategy was developed to target the most frequent point mutations in APDS1 (p.E1021K, c.3061G>A; ~90% of patients) and APDS2 (c.1425+1G > A; ~50% of patients). Highly efficient correction of the pathogenic point mutation was achieved in patient T cells and hematopoietic stem cells (HSCs) and associated with functional restoration of PI3K signaling, rescue of the activation-induced cell death phenotype and, in APDS2, abrogated expression of the pathogenic splice isoform. Edited HSCs maintained pluripotency and achieved long-term engraftment in immunodeficient mice. A healthy control:APDS1 mixed chimera mouse model suggested that 75% wild-type engraftment generated a wild-type phenotype with respect to T and B cell dysfunction and lymphoproliferation, and thus similar editing efficiencies would be predicted to improve patient clinical phenotype. Together, these data demonstrate successful application of base editing to a gain-of-function IEI, with potential for application in other diseases.
- Open Access
- 12 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (20) , 2497-2510
Functional restoration of immune defects in STAT1 gain-of-function disease after stem cell gene editing
Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in patients with STAT1 GOF mutations compared with those with other IEIs. To develop a curative, autologous alternative to HSCT, we evaluated gene-editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair were limited by low efficacy (<25%), poor viability, and a lack of allele specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (P< .0217), STAT1 phosphorylation (P< .0056), interferon-stimulated gene expression (OAS1; P = .0005), and improved interleukin-17 production (P< .0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. To our knowledge, this represents the first application of gene editing to correct a dominant GOF mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and GOF mutations.
- 12 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (20) , 2497-2510
Open AccessFunctional restoration of immune defects in STAT1 gain-of-function disease after stem cell gene editing
Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in patients with STAT1 GOF mutations compared with those with other IEIs. To develop a curative, autologous alternative to HSCT, we evaluated gene-editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair were limited by low efficacy (<25%), poor viability, and a lack of allele specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (P< .0217), STAT1 phosphorylation (P< .0056), interferon-stimulated gene expression (OAS1; P = .0005), and improved interleukin-17 production (P< .0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. To our knowledge, this represents the first application of gene editing to correct a dominant GOF mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and GOF mutations.
- 10 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1289-1291
Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity
Outcomes following international MDT assessment of adult IEI patients for allogeneic HSCT suggest early referral is vital: patients considered too high risk for transplant have poor outcomes with a 3-year overall survival of 31%.
- 10 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1289-1291
Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity
Outcomes following international MDT assessment of adult IEI patients for allogeneic HSCT suggest early referral is vital: patients considered too high risk for transplant have poor outcomes with a 3-year overall survival of 31%.
- 1 October 2020
- Published by Elsevier in Clinical Immunology
- Vol. 219, 108552
Transverse myelitis in a patient with activated phosphoinositide 3-kinase δ syndrome type 1
- 1 October 2020
- Published by Elsevier in Clinical Immunology
- Vol. 219, 108552
Transverse myelitis in a patient with activated phosphoinositide 3-kinase δ syndrome type 1
- 25 September 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (1) , 17-21
Haematopoietic stem cell transplantation in Tanzania
- 25 September 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (1) , 17-21
Haematopoietic stem cell transplantation in Tanzania
- 11 July 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (5) , E274-E276
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection
The COVID‐19 pandemic potentially makes treatment of acute leukaemia more difficult. Most induction chemotherapy regimens for acute leukaemia lead to extended periods of cytopaenia and immunosuppression rendering patients vulnerable to opportunistic infections. As with many aspects of SARS‐CoV‐2, there is no universally accepted way of treating patients who present with acute leukaemia and associated infection.
- 11 July 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (5) , E274-E276
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection
The COVID‐19 pandemic potentially makes treatment of acute leukaemia more difficult. Most induction chemotherapy regimens for acute leukaemia lead to extended periods of cytopaenia and immunosuppression rendering patients vulnerable to opportunistic infections. As with many aspects of SARS‐CoV‐2, there is no universally accepted way of treating patients who present with acute leukaemia and associated infection.